• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution
rhSOD

DRL announces the launch of Cefixime in the US

expressbpdAugust 29, 2017

Tag: DRL , Cefixime , FDA

DRL announces the launch of Cefixime in the US - BPD

Dr Reddy’s Laboratories (DRL) has launched Cefixime for Oral Suspension, USP 100 mg/5mL and 200 mg/5mL, a therapeutic equivalent generic version of Suprax for Oral Suspension, approved by the US Food and Drug Administration (USFDA).

DRL’s Cefixime for Oral Suspension, USP is available in strengths of 100 mg/5mL and 200 mg/5mL after reconstitution. The 100 mg/5 mL strength is available in 50 mL bottles. The 200 mg/5 mL strength is available in 75 mL and 50 mL bottles.

Previous:Jubilant Life gets US FDA nod for anti-inflammatory drug

Next:Danone India launches Neocate in India

Related News

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

A New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

DRL announces the launch of Cefixime in the US | Pharmasources.com

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

You may like
More>>

Cefixime

Cefixime
Medroxyprogesterone Acetate(FDA)

Medroxyprogesterone Acetate(FDA)
CEFIXIME

CEFIXIME
Fosphenytoin sodium (FDA)

Fosphenytoin sodium (FDA)
Etoposide( FDA)

Etoposide( FDA)
Vecuronium Bromide(FDA)

Vecuronium Bromide(FDA)
99% up GMP DMF Cefixime 79350-37-1

99% up GMP DMF Cefixime 79350-37-1
Aciclovir (FDA)

Aciclovir (FDA)
Cefixime for oral suspension 100mg/5ml

Cefixime for oral suspension 100mg/5ml
Praziquantel (FDA)

Praziquantel (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service